Why Vendor COAs Cannot Be Trusted: The Case for Independent Peptide Testing

If you have bought peptides, anabolic steroids, SARMs, or grey-market pharmaceuticals in the Philippines, you have almost certainly received a certificate of analysis (COA) along with your order. It looks official. It has chromatograms. It has a lab logo. It says purity 99.2 percent. It carries a signature and a stamp.

It also cannot be trusted as evidence. This article explains why a COA produced by, paid for by, or otherwise associated with the seller is structurally inadequate as quality verification, what fake COAs look like in actual circulation, and how independent third-party testing solves the problem that vendor COAs cannot.

This is not a theoretical concern. It is the daily operating environment of the Philippine peptide and anabolic market. an established international peptide-testing laboratory in Czechia, another international laboratory in the United States, and now Lumen Labs in the Philippines exist precisely because vendor COAs failed at scale, repeatedly, across compounds and across sellers.

For a complete walkthrough of how to read a real COA field by field, see how to read a certificate of analysis. This article is about why the COA in front of you may not be a real COA at all.

The conflict-of-interest problem

The structural argument is simple. A laboratory paid by the seller of a product to certify the quality of that product has a direct financial interest in producing favourable results. The buyer of the product has the opposite interest, an unfavourable result that exposes a counterfeit or adulterated product.

In every other industry where this conflict of interest exists, regulators have responded by separating the certifying entity from the seller. Building inspectors are not paid by the property owner. Auditors are not paid by the company they audit (and when they have been, history is full of corporate accounting fraud as a consequence). Drug-trial outcomes are reported to regulators independently of the manufacturer's marketing department.

In peptide and grey-market pharmaceutical sales, no such regulatory separation exists. The seller commissions the COA, pays the lab (if the lab even exists), and chooses whether to publish the result. The buyer has no leverage to demand independence.

The economic incentive aligns the seller and the lab against the buyer. This is not a moral judgement, it is a structural prediction. Across enough sellers and enough labs, the prediction is that some non-trivial fraction of vendor COAs will be misleading or outright fabricated, and the buyer cannot distinguish in advance which COAs are which.

The fake COA categories in actual circulation

Independent labs and pharmacovigilance agencies have catalogued the categories of fake or fraudulent COA documents in circulation. Filipino buyers see all of them.

Category 1: Pure fabrication. The COA was produced by a graphic designer, not a laboratory. Stock chromatograms are pasted in. The "lab" named on the document either does not exist, exists but did not produce the COA, or has had its identity stolen by the counterfeiter. The methodology section is generic copy-paste. The verification reference, if present, leads nowhere.

Category 2: Repurposed authentic COA. A real COA produced by a real laboratory for a real (passing) sample is duplicated, with the date and lot number altered, and applied to subsequent batches that may or may not match the original tested sample. The original COA is real; the application of it to the current batch is fraudulent.

Category 3: AI-generated COA. Since 2023, large language models and image generators are trivially capable of producing convincing-looking analytical chemistry documents. Chromatograms can be generated, methodology text can be written, even fake DOI references for fake supporting trials can be fabricated. The Philippine grey market has seen an uptick in AI-generated COAs since 2024.

Category 4: Real lab, real test, but the tested sample is not the sold sample. The seller submits a single high-quality reference sample to a real laboratory, receives a real COA, and uses that COA as marketing material for subsequent product runs that may or may not match. The COA is genuine; its application to the product you actually receive is not.

Category 5: Real lab, real test, but the lab is captive. A real laboratory has been engaged by the seller as a long-term contractor. The lab does real analysis but the results are filtered before publication, with the seller deciding which test results to disclose. Failures are quietly buried, passes are heavily promoted. The COA is genuine but the population of COAs the buyer sees is a curated subset.

Category 6: Methodology gaming. A real lab runs real methods, but the methods are chosen specifically to produce favourable results. Heavy metals tests with insufficient sensitivity that always pass. Purity tests at wavelengths that miss the major impurities. Identity tests that confirm the compound family but not the specific compound. The numbers are accurate within the methodology used; the methodology is inadequate.

In aggregate across the Philippine grey market, roughly half of vendor-supplied COAs the Lumen Labs team has examined fall into categories 1 through 4. The other half are in categories 5 and 6, or are genuine but inadequate documentation.

The economic logic for vendors

Faking a COA is rational from the seller's perspective. A counterfeit branded tirzepatide pen costs the counterfeiter perhaps PHP 800 to produce. Selling it requires a COA that looks credible. A graphic designer produces a fake COA for PHP 500 once, and the same template is reused across thousands of pens. The marginal cost of supplying a fake COA per pen is essentially zero.

Compare that to the cost of producing real-quality, defensible product. Authentic tirzepatide synthesis carries real cost-of-goods. Independent third-party testing of every batch costs USD 80 to 150 per test. Manufacturing under sterility-compliant conditions requires capital infrastructure. The honest path is more expensive than the dishonest path by a factor of ten or more.

In a market without regulatory enforcement, this cost differential drives a substantial fraction of supply toward the dishonest path. The market does not self-correct, because buyers cannot distinguish honest from dishonest sellers in advance and only learn after the purchase, often only through health consequences.

This is the same dynamic that operates in every market with information asymmetry. Akerlof's "Market for Lemons" paper from 1970 in the Quarterly Journal of Economics describes exactly this problem in used-car markets. The peptide market is the lemons market with stakes denominated in personal health rather than transmission failures.

What independent third-party testing actually does

Independent third-party testing breaks the conflict of interest by separating the analytical lab from the seller. The buyer pays the lab. The seller has no financial relationship with the lab. The lab's reputation depends on accuracy, not seller satisfaction.

an established international peptide-testing laboratory in Czechia pioneered this model in the European peptide and anabolic market. another international laboratory in the United States expanded it into the North American market. Lumen Labs operates the same model in the Philippines.

The defining features of independent third-party testing:

1. No commercial relationship with sellers. The lab does not sell, manufacture, distribute, or recommend any peptide, steroid, or pharmaceutical. The lab's revenue is entirely from analytical services.
2. Buyer-paid analysis. The buyer of the product, not the seller, commissions the test. The seller has no leverage to influence methodology, reporting, or disclosure.
3. Anonymised public results. Test results, with vendor names anonymised to letters, are published in a public database that anyone can browse. The aggregate pattern across vendors becomes visible to the entire community.
4. Publicly verifiable individual COAs. Each COA carries a task number and unique key. The buyer (and anyone with the document) can verify against the lab's records database. Forged documents fail the lookup.
5. Methodology transparency. Every COA names the analytical methods used (HPLC, LC-MS, GC-MS, ICP-MS, LAL, USP 61) with enough detail that a different lab could reproduce the result.
6. Validated reference standards. The lab uses reference standards from accredited sources, not standards supplied by the seller.

The combination of these features is what makes the COA defensible. None of them are present in a typical vendor-supplied COA.

What the Lumen Labs operating model looks like in practice

Lumen Labs operates as the Philippine analytical peer to international independent laboratories. Concretely:

• A buyer purchases a test on lumenlabs.ph and receives a sample-submission email with a task number and shipping address.
• The buyer ships the sample (vial, ampoule, tablet, raw powder) via LBC, J&T, DHL, or any tracked courier to our Manila lab.
• We run HPLC, LC-MS or GC-MS, and on request ICP-MS, LAL, or USP 61.
• Within 5 to 7 business days we issue a certificate of analysis with methodology, measured values, uncertainty range, and a verification reference.
• The COA is delivered to the buyer's email and through their customer-portal account.
• The anonymised result is published on the public results database.

We do not sell peptides. We do not recommend vendors. We do not have referral relationships with any seller. The output is the data on the sample, full stop. The decision of what to do with the data, whether to continue purchasing from a given source, whether to switch to a registered pharmacy, whether to discontinue, is the buyer's.

For the practical workflow of submitting a sample, see how to send a peptide sample to Lumen Labs. For the technical methodology, see how peptide testing works. For the broader context on counterfeit pharmaceuticals in the Philippines, see counterfeit pharmaceuticals Philippines.

How to use this in practice

For the Filipino buyer holding a vial with a vendor-supplied COA:

1. Treat the vendor COA as a marketing document, not as verification. Read it for what it claims, but do not rely on it as evidence.
2. Run the documentary checks. Methodology named? Verification reference? Real-looking lab? Date plausible? Most fake COAs fail at least one of these tests.
3. For any product sourced outside a registered pharmacy, run an independent test. One test per supplier. The cost is small relative to the cost of using an unverified product.
4. Use the public database. The Lumen Labs public COA database at /pages/results shows aggregated test results across vendors, anonymised but searchable. Patterns emerge that no individual buyer would see alone. For Filipino peptide communities running group orders, group testing splits the cost across users.
5. Refuse to buy from sellers who refuse independent testing. A seller's response to "may I send a sample to Lumen Labs first" is itself diagnostic. Sellers of authentic product have nothing to lose from a third-party test. Sellers of adulterated product have everything to lose.

Bottom line on vendor COAs

A vendor-supplied COA in the Philippine peptide market is a marketing document, not a verification document. The conflict of interest is structural, the economic incentives favour fabrication, and a meaningful fraction of vendor COAs in actual circulation are fake or fraudulent in one of six well-documented categories.

Independent third-party testing solves the problem by separating the lab from the seller. The running the same analytical workflow as international independent laboratories is Lumen Labs. The cost per test is low relative to the cost of buying and using an unverified product. The data is what allows a Filipino buyer to make an informed decision rather than a coin flip.

Disclaimer: Lumen Labs provides chemical analysis of submitted samples for harm-reduction and quality-verification purposes. We are not a substitute for medical care. We do not sell, supply, or recommend specific peptide, anabolic, or pharmaceutical products. Always consult a qualified Philippine licensed physician before starting any therapy.